Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralf W Dittmann

Showing results (21-30 of 76) with videos related to

Pageof 8
Sort By:
Pharmacoepidemiology and Drug Safety|August 26, 2017
Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
Pharmacoepidemiology and Drug Safety|November 22, 2016
Outpatient antidepressant drug use in children and adolescents in Germany between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
Psychiatry Research|February 27, 2010
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaDiego Novick, Josep Maria Haro, David Suarez, et al.
Journal of Child and Adolescent Psychopharmacology|June 16, 2017
Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
European Child & Adolescent Psychiatry|September 15, 2016
Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
CNS Drugs|May 27, 2016
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated DatabaseKatrien De Bruyckere, Chris Bushe, Christoph Bartel, et al.
International Clinical Psychopharmacology|October 16, 2004
Heart rate variability during sleep in patients with schizophrenia treated with olanzapineKlaus Mann, Wolfgang Rossbach, Matthias J Müller, et al.
Child and Adolescent Psychiatry and Mental Health|May 30, 2008
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)Peter M Wehmeier, Alexander Schacht, Martin Lehmann, et al.
Child and Adolescent Psychiatry and Mental Health|August 26, 2009
Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physiciansRalf W Dittmann, Peter M Wehmeier, Alexander Schacht, et al.
Journal of Child and Adolescent Psychopharmacology|March 5, 2008
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label studyPeter M Wehmeier, Ralf W Dittmann, Alexander Schacht, et al.
Pageof 8

Showing results (21-30 of 76) with videos related to

Sort By:
Pageof 8
Pharmacoepidemiology and Drug Safety|August 26, 2017
Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
Pharmacoepidemiology and Drug Safety|November 22, 2016
Outpatient antidepressant drug use in children and adolescents in Germany between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
Psychiatry Research|February 27, 2010
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophreniaDiego Novick, Josep Maria Haro, David Suarez, et al.
Journal of Child and Adolescent Psychopharmacology|June 16, 2017
Extent and Risks of Antipsychotic Off-Label Use in Children and Adolescents in Germany Between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
European Child & Adolescent Psychiatry|September 15, 2016
Outpatient antipsychotic drug use in children and adolescents in Germany between 2004 and 2011Carsten Schröder, Michael Dörks, Bianca Kollhorst, et al.
CNS Drugs|May 27, 2016
Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated DatabaseKatrien De Bruyckere, Chris Bushe, Christoph Bartel, et al.
International Clinical Psychopharmacology|October 16, 2004
Heart rate variability during sleep in patients with schizophrenia treated with olanzapineKlaus Mann, Wolfgang Rossbach, Matthias J Müller, et al.
Child and Adolescent Psychiatry and Mental Health|May 30, 2008
Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS)Peter M Wehmeier, Alexander Schacht, Martin Lehmann, et al.
Child and Adolescent Psychiatry and Mental Health|August 26, 2009
Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physiciansRalf W Dittmann, Peter M Wehmeier, Alexander Schacht, et al.
Journal of Child and Adolescent Psychopharmacology|March 5, 2008
Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label studyPeter M Wehmeier, Ralf W Dittmann, Alexander Schacht, et al.
Pageof 8